[1]Perz J F, Armstrong G L, Farrington L A, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide[J]. J Hepatol, 2006, 45(4): 529-538.
[2]Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection[J]. J Hepatol, 2014, 61(1 Suppl): S45-S57.
[3]Alter M J, Kuhnert W L, Centers for Disease Control and Prevention, et al. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus[J]. MMWR Recomm Rep, 2003, 52(RR-3): 1-13, 15.
[4]Oethinger M, Mayo D R, Falcone J A, et al. Efficiency of the ortho VITROS assay for detection of hepatitis C virus-specific antibodies increased by elimination of supplemental testing of samples with very low sample-to-cutoff ratios[J]. J Clin Microbiol, 2005, 43(5): 2477-2480.
[5]Kiri ci Ö, Calıskan A. Threshold value of the anti-HCV test in the diagnosis of HCV infection[J]. J Infect Dev Ctries, 2019, 13(10): 914-919.
[6]Pan J, Li X, He G W, et al. Reflex threshold of signal-to-cut-off ratios of the Elecsys anti-HCV II assay for hepatitis C virus infection[J]. J Infect Dev Ctries, 2016, 10(9): 1031-1034.
[7]中华医学会肝病学分会, 中华医学会感染病学分会. 《丙型肝炎防治指南》2019年版[J]. 中华传染病杂志, 2020, 38(1): 9-28.
[8]Kim M H, Kang S Y, Lee W I, et al. Evaluation of HCV RNA by PCR and signal-to-cutoff ratios of HCV antibody assays for diagnosis of HCV infection[J]. Lab Med, 2021, 52(3): 240-244.
[9]Liu H Y, Lin Y H, Lin P J, et al. Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection[J]. PLoS One, 2021, 16(7): e0254028.
[10]Choi M S, Lee K, Hong Y J, et al. The role of the signal-to-cutoff ratio in automated anti-HCV chemiluminescent immunoassays by referring to the nucleic acid amplification test and the recombinant immunoblot assay[J]. Ann Lab Med, 2018, 38(5): 466-472.
[11]Pawlotsky J M. Use and interpretation of virological tests for hepatitis C[J]. Hepatology, 2002, 36(5 Suppl 1): S65-S73.
[12]World Health Organization. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection: updated version[M]. Geneva: World Health Organization, 2016.
[13]袁梁, 张明新, 张韶娅, 等. 丙型肝炎病毒抗体阳性患者HCV-RNA与ALT结果分析[J]. 标记免疫分析与临床, 2022, 29(5): 736-741, 794.
[14]Lai K K Y, Jin M, Yuan S, et al. Improved reflexive testing algorithm for hepatitis C infection using signal-to-cutoff ratios of a hepatitis C virus antibody assay[J]. Clin Chem, 2011, 57(7): 1050-1056.
[15]Kim B, Ahn H J, Choi M H, et al. Retrospective analysis on the diagnostic performances and signal-to-cut-off ratios of the Elecsys Anti-HCV II assay[J]. J Clin Lab Anal, 2018, 32(1): e22165.
[16]Gupta E, Bajpai M, Choudhary A. Hepatitis C virus: screening, diagnosis, and interpretation of laboratory assays[J]. Asian J Transfus Sci, 2014, 8(1): 19-25.
[17]杨泽, 黎明新. ROC曲线对ECLIA法预测HCV感染的最佳S/CO值的确定和分析[J]. 检验医学与临床, 2020, 17(9): 1166-1168, 1172.
[18]潘洁. 罗氏丙肝抗体Ⅱ临界值的确立及几种丙肝抗体方法学比较[D]. 广东:南方医科大学,2018.
|